Literature DB >> 11863329

Systemic and local antibiotic prophylaxis in the prevention of prosthetic vascular graft infection: an experimental study.

F J Lehnhardt1, G Torsello, L G Claeys, M Pfeiffer, Z Wachol-Drewek, R T Grundmann, W Sandmann.   

Abstract

AIM: to determine if local, in addition to systemic antibiotic prophylaxis (compared to that provided by systemic prophylaxis alone) provides additional benefit in terms of reducing graft infection.
METHODS: gelatin-sealed Dacron grafts were interposed in the infrarenal aorta of 36 mongrels and inoculated with 1 ml of a S. aureus suspension. Group 1 (control group) received no prophylaxis and were inoculated with 1 ml containing 10(9)cfu/ml. Group 2 (n=6) received systemic prophylaxis (1 g cephamandole) and were inoculated with 10(5) cfu/ml (n=3) or 10(7) cfu/ml (n=3). Group 3 received systemic prophylaxis (1 g cephamandole) and were inoculated with 109 cfu/ml. Group 4 received systemic prophylaxis (2 g cephamandole) and were inoculated with 10(9)cfu/ml. In group 5 and 6 grafts were soaked in a rifampicin solution before use and inoculated with 10(9) cfu/ml. Group 5 received no systemic prophylaxis and group 6 received systemic prophylaxis (1 g cephamandole). Grafts were harvested at 2 weeks, and peritonitis, perigraft abscess, anastomotic disruption and graft occlusion recorded. Swabs were taken of the graft, the perigraft tissues and the peritoneal fluid. Graft segments were incubated in broth medium.
RESULTS: inoculation with 10(9) cfu/ml ensured graft infection. Systemic or local prophylaxis alone failed to prevent graft infection. Only systemic and local antibiotic prophylaxis provided significant better results than no prophylaxis at all (p<0.01) and local prophylaxis alone (p<0.05). However, total "graft sterility" was not achieved as bacteriologic analysis of the graft segments showed low bacterial counts (<10 bacteria/graft) in 5 of 6 grafts.
CONCLUSION: local and systemic prophylaxis provided more protection as demonstrated by the significant decrease in the incidence of "overt" graft infection. Total "graft sterility" cannot be expected in the case of an overwhelming bacterial challenge. Copyright 2002 Harcourt Publishers Limited.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11863329     DOI: 10.1053/ejvs.2001.1571

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  5 in total

1.  Novel fatty acid gentamicin salts as slow-release drug carrier systems for anti-infective protection of vascular biomaterials.

Authors:  A Obermeier; F D Matl; J Schwabe; A Zimmermann; K D Kühn; S Lakemeier; R von Eisenhart-Rothe; A Stemberger; R Burgkart
Journal:  J Mater Sci Mater Med       Date:  2012-04-03       Impact factor: 3.896

Review 2.  Group B streptococcus mycotic aneurysm of the abdominal aorta: report of a case and review of the literature.

Authors:  Shrey K Thawait; Aylin Akay; Ronen H Jhirad; Nayef El-Daher
Journal:  Yale J Biol Med       Date:  2012-03-29

3.  Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection.

Authors:  Huseyin Turgut; Suzan Sacar; Ilknur Kaleli; Mustafa Sacar; Ibrahim Goksin; Semra Toprak; Ali Asan; Nural Cevahir; Koray Tekin; Ahmet Baltalarli
Journal:  BMC Infect Dis       Date:  2005-10-21       Impact factor: 3.090

4.  Efficacy of linezolid, teicoplanin, and vancomycin in prevention of an experimental polytetrafluoroethylene graft infection model caused by methicillin-resistant Staphylococcus aureus.

Authors:  Bulent Mese; Orhan Bozoglan; Serdal Elveren; Erdinc Eroglu; Mustafa Gul; Ahmet Celik; Harun Ciralik; Halil Ibrahim Yildirimdemir; Alptekin Yasim
Journal:  Med Sci Monit       Date:  2015-03-27

5.  Treatment of vascular graft infections: gentamicin-coated ePTFE grafts reveals strong antibacterial properties in vitro.

Authors:  Igor Lazic; Andreas Obermeier; Bettina Dietmair; Wolfgang E Kempf; Albert Busch; Jutta Tübel; Jochen Schneider; Rüdiger von Eisenhart-Rothe; Peter Biberthaler; Rainer Burgkart; Dominik Pförringer
Journal:  J Mater Sci Mater Med       Date:  2022-03-10       Impact factor: 3.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.